Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study - Fifty-Two-Week Outcomes.

Debdulal ChakrabortyAniruddha MaitiJay Umed ShethSoumen MondalSubhendu BoralKrishnendu NandiTushar Kanti SinhaArnab Das

Published in: Clinical ophthalmology (Auckland, N.Z.) (2022)

The 52-week BRAILLE study demonstrates that brolucizumab is effective and safe in nAMD eyes in a real-world setting. Brolucizumab treatment can reduce the therapeutic burden in patients with nAMD due to its rapid, sustained efficacy and favourable safety profile.

Keyphrases

age related macular degeneration
type diabetes
clinical trial
metabolic syndrome
optical coherence tomography
adipose tissue
study protocol
skeletal muscle
vascular endothelial growth factor
smoking cessation
quantum dots
cataract surgery